Cannatrol Brings Breakthrough Postharvest Cannabis Tech to Europe in Partnership With Paralab Green
11.7.2024 15:03:00 EEST | Business Wire | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today an exclusive partnership with Paralab Green, Europe’s premier distributor of cannabis processing solutions, establishing distribution of the company’s patented Vaportrol® Technology throughout Europe.
“This partnership truly represents the best of cannabis processing,” said Jane Sandelman, CEO and Co-Founder of Cannatrol. “Paralab Green has established relationships within the European cannabis industry and has a unique understanding of the rapidly growing market. We look forward to opening international access to Cannatrol’s science-backed technology that will benefit cultivators—and ultimately consumers.”
Paralab Green supplies over 70% of licensed production facilities throughout the European Union, offering a range of instrumentation for the cannabis industry, from production to quality control.
“The European market continues to lead the way in Good Manufacturing Practices (GMP) compliance, and this partnership with Cannatrol is a pivotal addition that enhances our portfolio at Paralab Green,” said Rui Soares, CEO of Paralab Green. “The Cannatrol team brings invaluable scientific expertise to optimize and simplify the drying and curing process. This collaboration reinforces our commitment to excellence, raising industry standards and delivering exceptional value to our customers.”
Cannatrol systems ensure consistent water activity and vapor pressure, delivering elevated product quality, increased yields, GMP regulatory compliance and bottom-line improvements. Cannatrol’s patented postharvest technology is proven to increase curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition.
In addition to Europe, Paralab Green operates in Israel, North Africa and Latin America—opening the door for operators in those regions to access Cannatrol technology.
To learn more about Cannatrol’s Vaportrol® Technology, visit cannatrols.com.
About Cannatrol
Cannatrol supports commercial cannabis cultivation by streamlining and tightly controlling the critical drying, curing processes as well as postharvest storage. With patented Vaportrol® Technology, the system controls water loss by regulating the vapor pressure and ensures the correct final water activity, critical for terpene preservation, maximized potency, increased yield and premium quality. Cannatrol’s environmental control solution ensures consistent results for every climate and geography, taking the guesswork and risk out of seasonal humidity and temperature swings. Learn more at cannatrols.com.
About Paralab Green
Paralab Green, a division of Paralab with 32 years of industry leadership, specializes in providing innovative equipment solutions tailored for the cannabis industry. With a background in serving the pharmaceutical, biotechnology, energy, and chemical sectors, Paralab Green brings extensive expertise to cannabis cultivation, extraction, and production. Operating from offices in Portugal and Spain, we are the trusted solution provider for the majority of licensed producers in Europe. Paralab Green combines technical prowess with exceptional customer support to drive innovation and set new standards in the cannabis sector. Learn more at paralab-green.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711844879/en/
Contacts
Danna Tabachnik
Grasslands: A Journalism-Minded Agency
danna@mygrasslands.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 09:53:00 EEST | Press release
In an industry first, Ant International launched a full stack of AI-native solutions for payment, account, FX, treasury and growth operations for global businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917771311/en/ Peng Yang, CEO of Ant International, introduced the company’s payment foundation model at Ant International's 2026 global merchant event The AI-native product suite is built on a 2-layered security architecture, and our 2 proprietary foundation models: a payment foundation model (Antom 3-in-1 Transformer), and a time-series transformer (TST) forecasting model for FX and liquidity (FalconTST). Underpinning the FinAI stack are also 2 major pillars for payment interoperability for the AI era: our Agentic Mobile Protocol (AMP) and a blockchain-based wholesale settlement platform (WhaleRTP). This round of sweeping product upgrade aims to support all businesses with an AI action plan to complete two critic
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health system resilience and improving patient outcomes. These efforts focus on locally led solutions that enhance health infrastructure, prepare the healthcare workforce and leverage innovation to sustain essential services for climate-vulnerable communities. “Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom